Curis INC 8-K filings

NASDAQ

11 Jan 2024

CRIS

8-K: Curis Inc. Highlights Promising Clinical Data for Emavusertib in Leukemia and Lymphoma

Curis Inc.'s corporate presentation highlights the potential of their drug candidate, emavusertib, as a novel IRAK4 inhibitor with promising clinical data in leukemia and lymphoma.